CAMBRIDGE, Mass., Feb. 6, 2026 /PRNewswire/ — Insilico Medicine (“Insilico”)  (3696.HK),  a clinical-stage biotechnology company powered by generative artificialCAMBRIDGE, Mass., Feb. 6, 2026 /PRNewswire/ — Insilico Medicine (“Insilico”)  (3696.HK),  a clinical-stage biotechnology company powered by generative artificial

Insilico Medicine Appoints Halle Zhang, PhD (Med), as Vice President, Clinical Development – Oncology

2026/02/06 21:31
5 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

CAMBRIDGE, Mass., Feb. 6, 2026 /PRNewswire/ — Insilico Medicine (“Insilico”)  (3696.HK),  a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced the appointment of Halle Zhang, PhD (Med), as Vice President, Clinical Development – Oncology. Dr. Zhang will report to Feng Ren, Co-Chief Executive Officer and Chief Scientific Officer of Insilico Medicine, and will be based in the company’s Cambridge, Massachusetts office.

In this role, Dr. Zhang will lead the global clinical development strategy and execution for Insilico’s oncology portfolio, guiding both early- and late-stage programs across multiple tumor types. She will also contribute to broader portfolio planning and the company’s growth strategy, partnering closely with discovery, translational, biomarker, regulatory, and clinical operations teams to accelerate development timelines and deliver differentiated, patient-centered therapies.

Dr. Zhang is a strategic leader in oncology clinical development with more than 20 years of experience spanning academia, biotechnology, and the pharmaceutical industry. Most recently, she served as Global Clinical Development Program Leader for late-stage oncology and Global Program Leader for early oncology at Bristol Myers Squibb, where she was accountable for global development strategy and execution across multiple solid tumor indications, including lung, breast, melanoma, gastric, colorectal, bladder, and head and neck cancers. Her experience spans diverse therapeutic modalities, including immuno-oncology–based approaches, targeted small-molecule therapies, and antibody–drug conjugates (ADCs), leading programs from first-in-human studies through registrational trials.

She worked closely with global regulatory authorities to shape development strategies, optimize study design, and support regulatory submissions, while integrating translational science and biomarker strategies into clinical plans. Over the course of her career, she has built and scaled high-performing clinical development organizations and is recognized for fostering a culture of scientific rigor, accountability, and collaboration.

Earlier, Dr. Zhang held senior clinical development leadership roles at Infinity Pharmaceuticals and BioMed Valley Discoveries and began her career in academic research and clinical operations at Harvard Medical School, where she led NIH-sponsored clinical trials. She holds a PhD in Medicine and an MSc in Immunology and Microbiology from University of Birmingham, and a BSc in Nursing from University of Portsmouth.

“Halle brings exceptional scientific depth, strategic judgment, and operational excellence to Insilico’s oncology programs,” said Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine. “Her proven leadership across global oncology development will be instrumental as we continue to expand our AI-driven pipeline and translate innovative science into meaningful clinical outcomes for patients.”

“I am excited to join Insilico Medicine at such an important stage of growth,” said Dr. Zhang. “Insilico’s unique AI-driven platform, combined with a bold, science-first culture, creates a powerful opportunity to rethink how oncology medicines are discovered and developed. I look forward to partnering with this talented team to advance therapies that address significant unmet needs for patients.”

Over the past year, Insilico Medicine’s oncology pipelines have been moving forward with high efficiency. Several innovative pipelines designed and optimized with the help of Chemistry42 have progressed to Phase I clinical trials. In January 2025, ISM6331, a pan-TEAD inhibitor with an innovative structure, was announced to have completed first patient dosing in a global, multicenter Phase I clinical trial for the treatment of mesothelioma and other solid tumors. In June 2025, ISM3412, a potential “best-in-class” inhibitor targeting MAT2A, was announced to have completed first patient dosing in patients with locally advanced and metastatic solid tumors, aiming to evaluate safety, tolerability, PK/PD characteristics, and preliminary efficacy.

In addition to advancing its internal pipeline, Insilico Medicine and its global partners have achieved multiple milestones across collaborative oncology programs. The company entered a multi-program discovery and development collaboration with Servier valued at up to USD $888 million to leverage Insilico’s AI platform to generate first-in-class small-molecule cancer therapies. Under its collaboration totaling up to USD $550 million with Menarini Group, Insilico received a USD $3 million development and regulatory milestone payment in July 2025, followed by a USD $5 million milestone upon dosing the first patient in the Phase I clinical trial of MEN2501 (ISM9682), a highly differentiated KIF18A small-molecule inhibitor.

Harnessing state-of-the-art AI and automation technologies, Insilico has significantly improved the efficiency of preclinical drug development. While traditional early-stage drug discovery typically requires 3 to 6 years, from 2021 to 2024 Insilico nominated 20 preclinical candidates, achieving an average turnaround – from project initiation to preclinical candidate (PCC) nomination – of just 12 to 18 months per program, with only 60 to 200 molecules synthesized and tested in each program.

About Insilico Medicine

Insilico Medicine, a leading and global AI-driven biotech company, utilizes its proprietary Pharma.AI platform and cutting-stage automated laboratory to accelerate drug discovery and advance innovations in life sciences research. By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com.

Cision View original content:https://www.prnewswire.com/news-releases/insilico-medicine-appoints-halle-zhang-phd-med-as-vice-president-clinical-development–oncology-302681141.html

SOURCE Insilico Medicine

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

Unlimit Appoints Irene Skrynova as CEO, Global Payments

Unlimit Appoints Irene Skrynova as CEO, Global Payments

Unlimit announced the appointment of Irene Skrynova as CEO, Global Payments, as the company accelerates its evolution into a global financial infrastructure platform
Share
ffnews2026/03/12 18:17
Economic policies are chasing investors away from US – Mercer

Economic policies are chasing investors away from US – Mercer

The post Economic policies are chasing investors away from US – Mercer appeared on BitcoinEthereumNews.com. A wave of clients are shifting away from U.S. assets as investors react to President Donald Trump’s trade and interest-rate agenda, according to Mercer LLC. The consulting firm says concern over tariffs, pressure on the Federal Reserve, a swelling budget deficit and the risk of a softer dollar are pushing money to Europe, Japan and other markets. Hooman Kaveh, Mercer’s global chief investment officer, said a rising share of the firm’s 3,900 clients, together overseeing about $17 trillion, are reducing U.S. exposure. The opening weeks in the early phase of Trump’s second term “has been a trigger for genuine diversification,” he noted in an interview this week. “We’re certainly seeing that in client portfolios where flows are toward diversifying markets, geographies, asset classes, currencies.” Market nerves were evident in early April after Trump’s “Liberation Day” announcement, when both U.S. stocks and Treasuries fell before rebounding. Even so, U.S. shares have trailed many overseas benchmarks in 2025 for dollar-based investors. Kaveh said investors are struggling to price the tariff path because the effects can cut two ways: either squeeze company margins or get passed through to consumers and lift inflation. “If you have a situation where tariffs are going to push prices up, and the weaker dollar potentially can increase inflation, that would cause the Fed much more of a challenge to cut rates,” he added. As mentione in a Bloomberg report, he called the White House’s preference for a weaker dollar “the Achilles heel to the current approach” since it can magnify the inflation impulse from tariffs. Where the money is going Trump’s repeated criticism of Chair Jerome Powell, saying he has been slow to lower borrowing costs, along with the president’s move to fire Governor Lisa Cook, is further encouraging clients to step back from the U.S., according to…
Share
BitcoinEthereumNews2025/09/18 13:17
UiPath (PATH) Stock Slides 5% Despite Crushing Earnings on Every Metric

UiPath (PATH) Stock Slides 5% Despite Crushing Earnings on Every Metric

TLDR UiPath beat Q4 estimates with EPS of $0.30 vs $0.26 expected, and revenue of $481M vs $465M expected The stock fell more than 5% in premarket trading despite
Share
Coincentral2026/03/12 18:09